Affiliation
Department of Endocrinology, Christie Hospital, Manchester M20 4BX, UK.Issue Date
2007
Metadata
Show full item recordAbstract
Growth hormone replacement therapy has been used regularly in adult Growth hormone deficiency since the availability of recombinant GH in the 1980's. GH replacement improves quality of life, bone turnover markers, cardiovascular risk markers and adverse body composition. Originally, GH doses in replacement regimes were determined by weight and surface area and dose increases based on body composition outcomes analogous to pediatric practice. These regimens led to significant side effects related to excess GH, arthralgias, headaches and peripheral edema and IGF-I levels above the upper limit of the reference range. Newer treatment regimes therefore account for known factors affecting serum GH and IGF-I levels, i.e. age, gender, estrogen replacement and pre-treatment IGF-I levels. Monitoring is now via clinical symptomatology combined with serum total IGF-I levels, potentially this avoids excessive GH exposure and allows monitoring of compliance and dose titration. There is a lack of data relating IGF-I to biological endpoints, but analysis suggests that dose titration of IGF-I to the upper half of the age and gender related reference range is acceptable. The use of reliable IGF-I assays and extensive age and gender related reference ranges is necessary and centralized monitoring is preferable. Free IGF-I and bioavailable IGF-I measurements are available but their use in the monitoring of GH replacement remains to be determined.Citation
IGF-I measurements in the monitoring of GH therapy. 2007, 10 (2):159-63 PituitaryJournal
PituitaryDOI
10.1007/s11102-007-0027-9PubMed ID
17410471Type
ArticleLanguage
enISSN
1386-341Xae974a485f413a2113503eed53cd6c53
10.1007/s11102-007-0027-9
Scopus Count
Collections
Related articles
- Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
- Authors: Drake WM, Coyte D, Camacho-Hübner C, Jivanji NM, Kaltsas G, Wood DF, Trainer PJ, Grossman AB, Besser GM, Monson JP
- Issue date: 1998 Nov
- Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: a dose-finding study.
- Authors: Toogood AA, Shalet SM
- Issue date: 1999 Jan
- Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender.
- Authors: Rota F, Savanelli MC, Tauchmanova L, Savastano S, Lombardi G, Colao A, Di Somma C
- Issue date: 2008 Feb
- Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
- Authors: Fernholm R, Bramnert M, Hägg E, Hilding A, Baylink DJ, Mohan S, Thorén M
- Issue date: 2000 Nov
- Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement.
- Authors: Ahmad AM, Hopkins MT, Thomas J, Ibrahim H, Fraser WD, Vora JP
- Issue date: 2001 Jun